Literature DB >> 23303240

Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy.

Catherine Orrell1, Julie Levison, Andrea Ciaranello, Linda-Gail Bekker, Daniel R Kuritzkes, Kenneth A Freedberg, Robin Wood.   

Abstract

We examined HIV-1 resistance in children failing first-line and second-line antiretroviral therapy in South Africa, all with clade C virus. Those exposed to full-dose ritonavir had multiple protease resistance mutations. Nineteen percent had wild-type virus. Appropriate antiretroviral therapy sequencing in sub-Saharan African children is essential for prolong treatment options.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23303240      PMCID： PMC3881960          DOI： 10.1097/INF.0b013e3182829092

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  7 in total

1.  Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program.

Authors:  Carole L Wallis; Linda Erasmus; Sheba Varughese; Dalu Ndiweni; Wendy S Stevens
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

Review 2.  Update of the drug resistance mutations in HIV-1: December 2010.

Authors:  Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2010-12

3.  Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Authors:  Barbara S Taylor; Gillian Hunt; Elaine J Abrams; Ashraf Coovadia; Tammy Meyers; Gayle Sherman; Renate Strehlau; Lynn Morris; Louise Kuhn
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-23       Impact factor: 2.205

4.  Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

Authors:  Michael Tolle; Leigh Howard; Brianna Kirk; Andres Gomila; Heidi Schwarzwald; Gabriel Anabwani
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-10-04

5.  Protease inhibitor resistance in South African children with virologic failure.

Authors:  Gert U van Zyl; Lize van der Merwe; Mathilda Claassen; Mark F Cotton; Helena Rabie; Hans W Prozesky; Wolfgang Preiser
Journal:  Pediatr Infect Dis J       Date:  2009-12       Impact factor: 2.129

6.  A trial of three antiretroviral regimens in HIV-1-infected children.

Authors:  Katherine Luzuriaga; Margaret McManus; Lynne Mofenson; Paula Britto; Bobbie Graham; John L Sullivan
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

7.  HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.

Authors:  Visva Pillay; Candice Pillay; Rami Kantor; Francois Venter; Leon Levin; Lynn Morris
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205
  7 in total
  10 in total

1.  Explaining antiretroviral therapy adherence success among HIV-infected children in rural Uganda: a qualitative study.

Authors:  Peter K Olds; Julius P Kiwanuka; Norma C Ware; Alexander C Tsai; Jessica E Haberer
Journal:  AIDS Behav       Date:  2015-04

2.  Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.

Authors:  Jennifer Giandhari; Adriaan E Basson; Ashraf Coovadia; Louise Kuhn; Elaine J Abrams; Renate Strehlau; Lynn Morris; Gillian M Hunt
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-04       Impact factor: 2.205

3.  Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda.

Authors:  Peter K Olds; Julius P Kiwanuka; Denis Nansera; Yong Huang; Peter Bacchetti; Chengshi Jin; Monica Gandhi; Jessica E Haberer
Journal:  AIDS Care       Date:  2014-12-06

4.  Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.

Authors:  Jennifer Giandhari; Adriaan E Basson; Katherine Sutherland; Chris M Parry; Patricia A Cane; Ashraf Coovadia; Louise Kuhn; Gillian Hunt; Lynn Morris
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

5.  Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.

Authors:  Andrea L Ciaranello; Kathleen Doherty; Martina Penazzato; Jane C Lindsey; Linda Harrison; Kathleen Kelly; Rochelle P Walensky; Shaffiq Essajee; Elena Losina; Lulu Muhe; Kara Wools-Kaloustian; Samuel Ayaya; Milton C Weinstein; Paul Palumbo; Kenneth A Freedberg
Journal:  AIDS       Date:  2015-06-19       Impact factor: 4.177

6.  Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort.

Authors:  Sureshnee Pillay; Ruth M Bland; Richard J Lessells; Justen Manasa; Tulio de Oliveira; Sivapragashini Danaviah
Journal:  AIDS Res Ther       Date:  2014-01-20       Impact factor: 2.250

7.  High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study.

Authors:  Christian Diamant Mossoro-Kpinde; Jean-Chrysostome Gody; Ralph-Sydney Mboumba Bouassa; Olivia Mbitikon; Mohammad-Ali Jenabian; Leman Robin; Mathieu Matta; Kamal Zeitouni; Jean De Dieu Longo; Cecilia Costiniuk; Gérard Grésenguet; Ndèye Coumba Touré Kane; Laurent Bélec
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus.

Authors:  Sophie Desmonde; Simone C Frank; Ashraf Coovadia; Désiré L Dahourou; Taige Hou; Elaine J Abrams; Madeleine Amorissani-Folquet; Rochelle P Walensky; Renate Strehlau; Martina Penazzato; Kenneth A Freedberg; Louise Kuhn; Valeriane Leroy; Andrea L Ciaranello
Journal:  Open Forum Infect Dis       Date:  2019-06-11       Impact factor: 3.835

9.  High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.

Authors:  Kim Steegen; Leon Levin; Irene Ketseoglou; Michelle Bronze; Maria A Papathanasopoulos; Sergio Carmona; Wendy Stevens
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

10.  High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.

Authors:  Mounerou Salou; Anoumou Y Dagnra; Christelle Butel; Nicole Vidal; Laetitia Serrano; Elom Takassi; Abla A Konou; Spero Houndenou; Nina Dapam; Assetina Singo-Tokofaï; Palokinam Pitche; Yao Atakouma; Mireille Prince-David; Eric Delaporte; Martine Peeters
Journal:  J Int AIDS Soc       Date:  2016-04-27       Impact factor: 5.396
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.